<DOC>
	<DOC>NCT01871662</DOC>
	<brief_summary>The purpose of this study is to explore whether silibinin plus ribavirin with/without peg-interferon can be more effective than the peg-interferon plus ribavirin based standard of care (SoC) in the treatment of patients infected with hepatitis C virus genotype 4.</brief_summary>
	<brief_title>Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Silybin</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<criteria>Patient must be willing to give written informed consent Male and female patients; age between 21 and 45 years inclusive Chronic hepatitis C infection with genotype 4 confirmed by genotypic testing at screening or within 6 months of screening period Patients eligible to be treated with RBV and PegIFN as per the instructions present in their prescribing information documents No history of prior interferon therapy (treatment naïve) Detectable HCVRNA levels Normal BUN and creatinine Ability to communicate, participate, and comply with the requirements of the entire study Liver transplant patients CoInfection with HIV and/or HBV ALT &gt;10fold the upper limit of normal i.e. &gt; 400 U/L Evidence of hepatocellular carcinoma (HCC) Fibroscan® at screening with a score ≥ 14.5 kPa Evidence of liver disease due to causes other than chronic HCV infection Evidence of poorly controlled diabetes (defined as HbA1c &gt; 8%) History of alcohol or drug abuse within the last 12 months History or clinical evidence of liver decompensation, e.g. presence of ascites or encephalopathy, or bleeding from esophageal varices Serum albumin levels &lt; 3.2 g/dL INR &gt; 1.3 N Total Bilirubin levels &gt; 2.0 mg/dL unless explained by Gilbert's disease Platelet Count &lt; 100,000 µL Absolute Neutrophil counts &lt; 1500 µL (mm3) Active or suspected nonhepatic malignancy or history of malignancy within the last 5 years Body Mass Index &lt; 16 or &gt; 35 kg/m2 Females of childbearing potential: Pregnancy (i.e. positive urine pregnancy test at screening) or lactation Failure to agree to practice adequate contraception methods (e.g. oral contraceptives, intrauterine device (IUD), transdermal contraceptive patch) Male patients not vasectomized, who do not agree to abstain from intercourse or who do not use a condom</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>